We here demonstrated in a large patient cohort, that Tak1 is activated in HCC independent of its etiology, further upregulated in distant metastases, and that activation of the Cyld-Tak1 pathway is associated with short patient survival, increased proliferation and vascular invasion. Here, CYLD is linked to hepatocellular carcinoma.